Number of the records: 1  

Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response

  1. 1.
    ADKINS, I., SADÍLKOVÁ, I., HRADILOVÁ, N., TOMALA, Jakub, TOMALOVÁ, Barbora, KOVÁŘ, Marek, MIKYSKOVÁ, R., REINIŠ, Milan, DE MARTYNOFF, G., BECHARD, D., MOEBIUS, U., SPÍŠEK, R. Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response. Cancer Research. 2018, 78(13 S). ISSN 0008-5472. E-ISSN 1538-7445. Available: doi: 10.1158/1538-7445.AM2018-3775
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.